Royalty Pharma plc
HealthcareNASDAQ:RPRX · NASDAQ Global Select
-$0.42 today
Vol 3.07M · Avg 3.65M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
11.9%
avg 17.7%
ROIC
8.9%
avg 9.3%
ROA
3.9%
avg 7.1%
Analysis
ROE is currently the strongest return metric at 11.9% versus its period average of 17.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Pablo Legorreta | Founder, Chairman of the Board & Chief Executive Officer | $44.02M | — | 63 | $1.24M | 0.29% |
James Folmar Reddoch | Executive Vice President of Investments & Chief Scientific Officer | $3.40M | — | 56 | $478,870.00 | 0.11% |
Arthur Richard McGivern | Executive Vice President of Investments & Chief Scientific Officer | $3.40M | — | 51 | $0.00 | <0.01% |
Christopher Hite | Chairman of Partnering & Investments | $1.32M | — | 59 | $709,399.00 | 0.16% |
Terrance Coyne | Executive Vice President & Chief Financial Officer | $1.32M | — | — | $0.00 | <0.01% |
Marshall Urist | Executive Vice President of Research & Investments | $1.32M | — | 50 | $18,197.00 | <0.01% |
Eric Cornelius Schneider | Senior Vice President & Chief Technology Officer | — | — | — | — | — |
Sandy Balkin | Senior Vice President of Strategy & Analytics | — | — | — | — | — |
George Grofik | Senior Vice President and Head of Investor Relations & Communications | — | — | — | $0.00 | <0.01% |
Molly Sawaya | Executive Vice President & Head of Human Capital | — | — | — | — | — |
Sara Klymkowsky | Senior Vice President of Research & Investments | — | — | — | — | — |
Sam Landsberg | Finance and Treasurer | — | — | — | — | — |
Kenneth Siming Sun | Senior VP & Head of Asia | — | — | — | — | — |
Ashwin Pai | Executive Vice President of Investments & Partnering | — | — | — | — | — |
Lucas Glass | Head of Artificial Intelligence | — | — | — | — | — |
Scott Raichilson | Chief Accounting Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
60
$64.55M
Net Sentiment
$64.55M
Net selling
Most Active
Coyne Terrance P.
33 transactions
1–10 of 60
Analysis
Insiders reported 0 buys worth $0.00 and 60 sells worth $64.55M over the last 12 months. That adds up to net selling of $64.55M. Coyne Terrance P. was the most active insider with 33 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +92.5% | +1.4% (11yr)1 analysts |
| Revenue | N/A | N/A | -1.1% | +9.6% (11yr)1 analysts |
| Net Income | N/A | N/A | +60.7% | +5.7% (11yr)1 analysts |
| EBIT | N/A | N/A | +53.7% | +1.1% (11yr)1 analysts |
Analysis
Recent growth has been strongest in EPS at +92.5% over three years. Forward estimates point to Revenue at +9.6% (11yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
United Therapeutics Corporation
NASDAQ:UTHR
$23.17B
Incyte Corporation
NASDAQ:INCY
$21.68B
Roivant Sciences Ltd.
NASDAQ:ROIV
$21.61B
Hologic, Inc.
HOLX
$16.97B
Genmab A/S
NASDAQ:GMAB
$15.40B
Tenet Healthcare Corporation
NYSE:THC
$15.04B
Exelixis, Inc.
NASDAQ:EXEL
$13.35B
Smith & Nephew plc
NYSE:SNN
$12.97B
Fresenius Medical Care AG & Co. KGaA
NYSE:FMS
$12.36B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.86B
Who manages RPRX?
Royalty Pharma plc (RPRX) lists 16 active executives. The top listed executive is Pablo Legorreta, Founder, Chairman of the Board & Chief Executive Officer.
Are RPRX insiders buying or selling?
Recent insider activity shows net selling of $109.91M.
Explore More
Continue the stock analysis
Jump to another research area for this company.